The Relation Between Vitamin D Production and UVB Exposed Body Surface Area
NCT ID: NCT01042197
Last Updated: 2010-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
92 participants
INTERVENTIONAL
2008-01-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Vitamin D Dose-Response Relationship
NCT01074541
Maintenance of Vitamin D Level by UVB Radiation
NCT01101243
Does Sunbed Radiation With Mainly UVA Provoke Cutaneous Vitamin D Synthesis in Humans?
NCT00516867
The Influence of Skin Pigmentation on UVB Induced Vitamin D Increase
NCT03409510
Production of Vitamin D Metabolites by UV-radiation From Solar Bed
NCT01261039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Body surface area: 12 %
Broadband UVB
UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
1
Body surface area: 6 %
Broadband UVB
UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
3
Body surface area: 24 %
Broadband UVB
UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
4
Body surface area: 6 %
Broadband UVB
UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
5
Body surface area: 12 %
Broadband UVB
UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
6
Body surface area: 24 %
Broadband UVB
UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
7
Body surface area: 6 %
Broadband UVB
UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
8
Body surface area: 12 %
Broadband UVB
UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
9
Body surface area: 24 %
Broadband UVB
UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Broadband UVB
UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Broadband UVB
UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Avoidance of sun bed exposure
* Not Holidaying south of 45 degrees latitude 3 months before
* Avoiding vitamin D supplementation during and two months before
Exclusion Criteria
* Skin diseases
* Psychiatric diseases
* Drug addiction
* Intake of photosensitive medicine.
* Intake of cholesterol-lowering medicine.
* Pregnancy
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vejle Hospital
OTHER
Bispebjerg Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bispebjerg Hospital, Department of Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans Christian Wulf, Full Prof.
Role: STUDY_CHAIR
Bispebjerg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bispebjerg Hospital, Department of Dermatology D92, Bispebjerg Bakke 23,
Copenhagen Nv, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-B-2007-100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.